| CAS NO: | 486-66-8 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 100g | 电议 |
| Molecular Weight (MW) | 254.24 |
|---|---|
| Formula | C15H10O4 |
| CAS No. | 486-66-8 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 51 mg/mL (200.6 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | Chemical Name: 4',7-Dihydroxyisoflavone InChi Key: ZQSIJRDFPHDXIC-UHFFFAOYSA-N InChi Code: InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H SMILES Code: O=C1C(C2=CC=C(O)C=C2)=COC3=C1C=CC(O)=C3 |
| Synonyms | Daidzein; Daidzeol; Isoaurostatin |
| In Vitro | In vitro activity: Daidzein inhibits iNOS protein and mRNA expression and also NO production in a dose-dependent manner. Daidzein also inhibits the activation of the signal transducer and activator of transcription 1 (STAT-1), another important transcription factor for iNOS. Daidzein (1 μM and 10 μM) causes a significant elevation of protein content, alkaline phosphatase activity, and DNA content in cells; those increases are about 1.4-, 1.5-, and 2.0-fold, respectively. Daidzein (2-50 mM) increases the viability of osteoblasts by about 1.4-fold. Daidzein (2-100 mM) increases the alkaline phosphatase activity and osteocalcin synthesis of osteoblasts by about 1.4- and 2.0-fold, respectively. Daidzein stimulates osteoblast differentiation at various stages (from osteoprogenitors to terminally differentiated osteoblasts). Daidzein (1 μM and 10 μM) causes a significant increase of alkaline phosphatase activity, deoxyribonucleic acid (DNA) and calcium contents in bone tissues. Daidzein-induced increase of calcium content and alkaline phosphatase activity in bone tissues is completely prevented by cycloheximide (1 μM). |
|---|---|
| In Vivo | Daidzein results in reduced body weight, a fact that may be explained by reduced feed consumption in female rats. Daidzein results in slight, but not significant, decreases in ovarian and uterine weights, and mammary gland size in female rats. |
| Animal model | Rats |
| Formulation & Dosage | |
| References | Mediators Inflamm. 2007;2007:45673; Biochem Pharmacol. 2000 Mar 1;59(5):471-5; Toxicol Sci. 2002 Feb;65(2):228-38. |
m.cnreagent.com